Previous Article | Next Article 
Journal of Clinical Microbiology, January 2001, p. 266-269, Vol. 39, No. 1
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.1.266-269.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Fecal Leukocyte Stain Has Diagnostic Value for
Outpatients but Not Inpatients
Kristen L.
Savola,1
Ellen Jo
Baron,1,2,*
Lucy S.
Tompkins,1,2 and
Douglas J.
Passaro1
Departments of Infectious
Diseases1 and
Pathology,2 Stanford University Medical
Center, Stanford, California 94305-5250
Received 28 June 2000/Returned for modification 4 September
2000/Accepted 17 October 2000
 |
ABSTRACT |
The methylene blue stain for fecal leukocytes (FL) is widely used
as an adjunct to slower but more accurate tests of diarrheal etiology,
such as stool culture (SCx) or toxin assays for Clostridium difficile. Prior studies investigating the utility of FL for
predicting SCx and C. difficile toxin assay (CDTA) results
did not evaluate the importance of inpatient versus outpatient status.
We conducted a study of patients who submitted a stool specimen to the
Stanford Hospital Microbiology Laboratory between May 1998 and April
1999. The results for stool specimens that were tested by FL and by a
confirmatory test (either SCx or CDTA) were used to determine whether
the FL method helped to predict the results of these tests. Of 797 stools that were tested by FL method and at least one confirmatory test, 502 stools were tested by CDTA, and 473 stools were cultured. The
FL test was 14% sensitive and 90% specific for C. difficile with a diagnostic threshold of one white blood
cell/high-power field (WBC/HPF). The overall likelihood ratio (LR) for
a positive CDTA was 1.4 with a 95% confidence interval (CI) of 0.5 to
3.7 (P = 0.5) and was similar among inpatients and
outpatients. In contrast, the presence of
1 WBC/HPF was 52%
sensitive and 88% specific for the 27 positive SCx results and helped
to predict a positive SCx result (LR, 4.2; 95% CI, 2.7 to 6.5;
P < 0.001). The sensitivity of
1 WBC/HPF was 57%,
and its predictive value for SCx was higher among outpatients
(outpatient LR, 5.0; 95% CI, 2.9 to 8.6; P < 0.001;
inpatient LR, 1.9; 95% CI, 0.3 to 10.8; P = 0.5).
Among inpatients, only 4 (1.5%) of the 273 SCx results were positive,
and the presence of
1 WBC/HPF was insensitive (25%) and did not
predict a positive SCx (LR, 1.9; 95% CI, 0.3 to 10.8;
P = 0.5). When the data were reanalyzed using a
diagnostic threshold of five WBC/HPF for FL, the predictive power of
the FL method was similar. Thus, FL was of no value in predicting CDTA
positivity, nor was it helpful in predicting SCx results for
inpatients. Neither SCx nor the FL method should routinely be performed
on samples from inpatients. Among outpatients, presence of FLs should
suggest a bacterial diarrhea in clinically compatible cases.
 |
INTRODUCTION |
Diarrhea still remains a common
complaint of both hospitalized patients and patients seen in an
outpatient setting. Standard tests for determining diarrheal etiology,
such as stool culture (SCx) and the Clostridium difficile
cytotoxin detection assay (CDTA), are accurate but generally too slow
to be helpful to the clinic or emergency room physicians who are
diagnosing and treating the patient. This has led to the use of several
more rapid tests (fecal leukocyte [FL] stain, fecal occult blood
test, fecal lactoferrin test) that are currently used to suggest
disease with a bacterial pathogen while awaiting stool culture results.
Unfortunately, these tests are not predictive in all situations
(4-6, 10-11).
The methylene blue stain for FLs represents a widely used adjunct to
slower but more accurate tests of diarrheal etiology, such as SCx or
CDTA. Willmore and Shearman (15) first described the FL
stain in 1918 to help identify bacillary and amebic dysentery. In 1972, Harris et al. (4) found that the presence of FLs indicated a bacterial cause of acute diarrhea in 89% of cases. FLs were also
found in up to 50% of cases of C. difficile infection
(1).
Despite the widespread use of FLs to predict a positive SCx, recent
studies have found conflicting results (5-6, 10, 12). Similarly, the performance characteristics of FLs for predicting C. difficile infection have varied widely (2,
7). One reason for the conflicting results may be that these
studies were performed in a variety of settings, both inpatient and
outpatient, with various criteria for ordering the tests. No studies
have directly compared the utility of FLs for predicting CDTA and SCx
results by patient location. To define the most appropriate clinical
setting for ordering these tests, we examined the utility of FL for
predicting CDTA and SCx results among inpatients and outpatients at our
hospital. Furthermore, published threshold values define a
"positive" test range from
1 white blood cell/high-power field
(WBC/HPF) (12, 17) to >50 WBC/HPF (13).
Since a prior comparison of diagnostic threshold values did not
identify a superior cutoff (10), we used both
1 and
5
WBC/HPF values as FL threshold values to determine which is more
clinically useful.
(These results were presented, in part, as an abstract at the 1999 annual meeting of the Infectious Diseases Society of America [abstr.
259, p. 84].)
 |
MATERIALS AND METHODS |
Study population.
We conducted a retrospective cohort study
of all patients who submitted a diagnostic stool specimen to the
Stanford Hospital Clinical Microbiology Laboratory from 1 May 1998 through 30 April 1999. Patients who submitted a stool sample for FL
analysis and either CDTA, SCx, or both methods were included in the
study. The decision to order a stool study was made by the patient's clinician. A maximum of one stool sample per patient (the first sample
collected) was analyzed. Stool samples that were described as "formed
stool without blood" by the laboratory were excluded. Patient
location (inpatient or outpatient status) was assessed, but the acuity
of illness and length of stay at the time of sample collection was not.
Outpatient location included specimens received either from the
emergency department or from hospital-associated outpatient clinics.
Testing characteristics (sensitivities, specificities, and likelihood
ratios [LRs]) for FL were compared with the presence of C. difficile toxin and SCx results for both inpatients and outpatients.
FL method.
One drop of fresh (<3 h since collection) stool
was mixed with an equal proportion of Loeffler's methylene blue stain
(0.2% methylene blue). The suspension was examined under high-dry
power (HPF) (×400) for the presence of polymorphonuclear leukocytes (WBCs). Positive results were analyzed at either
1 or
5 WBC/HPF.
SCx method.
All stool specimens submitted either fresh (<3
h since collection) or in Cary-Blair preservative were inoculated onto
Trypticase soy agar with 5% sheep blood, MacConkey agar, Hektoen
Enteric, MacConkey sorbitol (if stool was either unformed or formed
with blood, for Escherichia coli O157:H7), and brucella
blood agar with trimethoprim, vancomycin, and polymyxin (for
Campylobacter) plates. If Vibrio sp. was
suspected clinically, TCBS agar was added. Plates were incubated in air
at 35°C except for the Campylobacter plates, which were
incubated in a microaerophilic atmosphere at 42°C. All plates were
examined daily for 3 days before discarding them as negative. Sweep
oxidase testing from the blood agar was used to detect
Aeromonas, Plesiomonas, and Vibrio
spp. Suspicious colonies were identified using standard methods
(9). This method is able to detect Salmonella,
Shigella, Aeromonas, Plesiomonas, Campylobacter, Vibrio, or Yersinia
species and E. coli O157:H7 (in unformed or formed bloody stools).
Toxin assays for C. difficile.
The Stanford
Hospital Microbiology Laboratory refrigerated fresh stool specimens at
4°C immediately upon receipt. The stool was diluted 1:6, and filtrate
was used to inoculate tissue culture tubes containing human diploid
embryonic fibroblast (MRC-5) cell culture monolayers. Each sample was
tested in duplicate: stool only and stool plus cytotoxin B antitoxin
(Tech Lab, Blacksburg, Va.) Tubes were incubated at 35°C and examined
microscopically three times daily for 2 days for typical toxin
cytopathic effect (CPE) and neutralization of toxicity. The presence of
CPE in stool filtrate and the absence of CPE in the corresponding
antitoxin-containing tube was considered positive for C. difficile toxin B. If the CDTA showed nonspecific toxicity, the
original stool (from a frozen aliquot) was tested for cytotoxin A using
the Meridian Immunocard Toxin A Test (Meridian Diagnostics, Kansas
City, Mo.). A positive result by either method was considered positive
for C. difficile toxin.
Statistical analysis.
Results from all stool specimens
entered into the database of the Stanford University Diagnostic
Microbiology Laboratory were analyzed (Stata 6.0; College Station,
Tex.) after expunging personal identifiers. Only the first unformed
specimen from each patient was analyzed, and only if the specimen was
tested for FLs in conjunction with either or both CDTA and SCx methods.
LRs for each test were calculated as follows: LR = [sensitivity/(1
specificity)] (3). The LR is a
predictive number that evaluates the utility of the test for
evidence-based clinical decision-making. Briefly, the pretest odds of a
specific outcome (e.g., being infected with Campylobacter
sp.), multiplied by the LR, yields the posttest odds of that outcome.
The utility of FL for predicting C. difficile disease or
bacterial diarrhea was analyzed separately, despite the fact that some
specimens had both the CDTA and the SCx ordered. Results are presented
for each subgroup (FL method versus CDTA and FL method versus SCx)
separately, resulting in total numbers higher than the number of
specimens (see Tables 1 and 2).
 |
RESULTS |
Of 797 stools that were tested by the FL method and at least one
confirmatory test, 502 were tested by CDTA, 473 were cultured, and 238 were tested by both methods (Table 1). Of
the 502 tested by CDTA, 409 (81%) were inpatients and 93 (19%) were
outpatients. Of the 473 tested by SCx, 273 (58%) were inpatients and
200 (42%) were outpatients (Table 1). The prevalence of a positive
CDTA result was 6% (29 of 502). The prevalence of a positive SCx in this population was also 6% (27 of 473). The most common bacterial pathogens isolated were Campylobacter spp. (11 isolates) and
Shigella spp. (8 isolates), followed by
Salmonella spp. (3 isolates), E. coli O157:H7 (2 isolates), and Aeromonas, Vibrio, and
Yersinia spp. (1 isolate each). Of all specimens tested by
either CDTA, SCx, or both, 12% (97 of 797) were positive for FLs.
Overall, 56 (10%) of 542 inpatients and 41 (16%) of 255 outpatients
were positive for FLs (Table 1).
FLs for the diagnosis of C. difficile infection.
The presence of
1 WBC/HPF was only 14% sensitive and 90% specific
for C. difficile and did not predict the 29 positive CDTA results (LR, 1.4; 95% confidence interval [CI], 0.5 to 3.7) (Table 2). The sensitivity and specificity did
not vary with patient location (Table 2), nor did it vary significantly
when analyzing the subgroup of 234 patients with negative SCx results,
from which 11 specimens were CDTA positive and 4 of the 11 had FLs. Of
the 223 CDTA-negative specimens, 40 (18%) also had a positive FL
result. A stricter threshold of
5 WBC/HPF was less sensitive than the
1 WBC/HPF for predicting a positive CDTA result. The presence of
5
WBC/HPF predicted 2 of 21 (10%) inpatients to be positive for C. difficile, none of 8 outpatients, and 2 (7%) of all 29 patients
with positive CDTA results. The LRs for each group were not different
from those with only
1 WBC/HPF (Table 2).
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Sensitivity and specificity of FLs for predicting a
positive CDTA or the presence of enteric pathogen on SCx
|
|
FLs for the diagnosis of enteroinvasive bacterial diarrhea.
A
total of 1% (4 of 273) of inpatients and 12% (23 of 200) of
outpatients had a positive SCx (Table 1). The FL test was positive in
14 (52%) of 27 specimens yielding an enteric pathogen but was also
positive for 55 (12%) of 446 with negative cultures (Table 1). The
sensitivity of
1 WBC/HPF for predicting a positive SCx result was
twice as high (57%) among outpatients as among inpatients (25%) with
similar specificities (Table 2). Moreover, the presence of
1 WBC/HPF
had predictive value for SCx for outpatients (LR, 5.0; 95% CI, 2.9 to
8.6; P < 0.001) but not for inpatients (LR, 1.9; 95%
CI, 0.3 to 10.8; P = 0.5). Among outpatients, using
5 WBC/HPF decreased the sensitivity but not the predictive value (LR,
5.1; 95% CI, 2.5 to 10; P < 0.001) (Table 2). Of 234 culture-negative specimens for which CDTA tests were also ordered, the
sensitivity of either WBC threshold for predicting a positive CDTA
result was 18% (2 of 11 specimens), and the specificities for
1 and
5 WBC/HPF were 87% (194 of 223) and 95% (212 of 223), respectively.
 |
DISCUSSION |
This study is the first to compare the utility of FL for
predicting CDTA and SCx results by patient location. Prior studies have
not stratified patients by admission status and have drawn different
conclusions about the utility of the FL method in the evaluation of
diarrhea (1-2, 4-6, 10, 12, 17). We also sought to
determine which diagnostic threshold,
1 or
5 WBC/HPF, is more
clinically useful since previous studies have not answered this
question (5, 10).
Based on our data, routine use of the FL method for patients with a
clinical suspicion of C. difficile infection is not
indicated. The FL method was a poor predictor of C. difficile infection overall, regardless of the patient status.
Moreover, the sensitivities and LRs remained poor even in the subgroup
of patients with negative stool cultures, a group one might expect to
have C. difficile infection as an alternative explanation
for their diarrhea. Decreasing the threshold for a positive result from
5 to
1 WBC/HPF did not improve the predictive value of the test.
Because the sensitivity of FL for C. difficile was low and
because the FL test did not predict C. difficile results in
inpatients or outpatients, we would not advocate ordering the FL test
in any setting to evaluate for C. difficile infection. Our
laboratory no longer accepts such requests.
In this study we found, as have others, that SCx results are rarely
positive for inpatients (12, 14). This is not surprising since bacterial diarrheas are rarely nosocomial. Of the small number
that was positive, the FL test was a poor predictor. Among outpatients,
however, the presence of
1 WBC/HPF was positive in >50% of
specimens with positive SCx results and was statistically significantly
associated with a positive result (LR, 5.0; 95% CI, 2.9 to 8.6;
P < 0.001). Furthermore, the utility of the FL method
was similar regardless of the threshold used. Thus, if a clinician
strongly suspects a bacterial diarrhea and the FL test is positive, it
is more likely that the patient will have a positive stool culture.
Moreover, the negative predictive values for either FL threshold are
high (94 and 92%, respectively). A negative FL test in an outpatient
suspected of having bacterial diarrhea suggests that the suspected
etiology is incorrect. Based on such a result, the clinician may opt
not to treat the patient with antibiotics while awaiting the culture
result or not to order a stool culture at all.
The low prevalence of positive CDTA or SCx results at our institution
(6%) may explain in part why the FL test was not more sensitive. These
prevalences are similar to those in most U.S. institutions
(14). This implies that too many tests are being ordered
and that, perhaps, in addition to better screening tests for
inpatients, better prediction rules are needed at our institution. For
example, prior studies have found that factors such as hospital readmission status, leucocytosis, cephalosporin use, prolonged hospital
stay, and the onset of diarrheal symptoms at >6 days after the
administration of antibiotics are predictive of a positive C. difficile toxin result (2, 7). Rigorous guidelines
incorporating such risk factors could help define patients who warrant
further testing for the evaluation of their diarrhea and could increase the cost-effectiveness of such tests. Importantly, the present study is
too small to address the relevance of FLs in predicting verotoxigenic
E. coli infection, where antibiotics are contraindicated or
Salmonella infection, where antibiotics are of limited
usefulness (16). In fact, the FL test may be more useful
for predicting the course and severity of disease and less useful for
identifying the need for antibiotics.
This study is the first to show that differences in the usefulness of
the FL test may reflect the type of diarrhea the patient has (whether
C. difficile diarrhea or some other type of diarrhea). Specifically, this study showed that the FL test is of minimal use in
the detection of C. difficile infection regardless of who is
tested or how a positive test is defined. Moreover, SCx results are
rarely positive in inpatients, and physicians should not order them.
Fortunately, most laboratories appropriately limit such tests to
samples from patients within 3 days of admission (9, 14).
On the other hand, judicious use of the FL test for the evaluation of
diarrhea in the clinic or emergency department, when combined with
clinical and laboratory parameters, may help to suggest appropriate
treatment strategies. Nevertheless, better screening tests and clinical
prediction rules are needed.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Clinical
Microbiology/Virology Laboratory, Stanford University Hospital, Rm.
H1537-J, MC 5629, 300 Pasteur Dr., Stanford, CA 94305-5250. Phone:
(650) 725-3773. Fax: (650) 725-5671. E-mail:
ejbaron{at}stanford.edu.
 |
REFERENCES |
| 1.
|
Bartlett, J. G.
1992.
Antibiotic associated diarrhea.
Clin. Infect. Dis.
15:573-581[Medline].
|
| 2.
|
Cooper, G. S.,
M. M. Lederman, and R. A. Salata.
1995.
A predictive model to identify Clostridium difficile toxin in hospitalized patients with diarrhea.
Am. J. Gastoenterol.
91:80-84.
|
| 3.
|
Gray, G.,
J. Struewing,
K. C. Hyams,
J. Escamilla,
A. K. Tupponce, and E. L. Kaplan.
1993.
Interpreting a single antistreptolysin O test: a comparison of the "upper limit of normal" and likelihood ratio methods.
J. Clin. Epidemiol.
46:1181-1185[CrossRef][Medline].
|
| 4.
|
Harris, J. C.,
H. L. Dupont, and R. B. Hornick.
1972.
Fecal leukocytes in diarrheal illness.
Ann. Intern. Med.
76:697-703.
|
| 5.
|
Huicho, L.,
M. Campos,
J. Rivera, and R. L. Guerrant.
1996.
Fecal screening tests in the approach to acute infectious diarrhea: a scientific overview.
Pediatr. Infect. Dis. J.
15:486-494[CrossRef][Medline].
|
| 6.
|
Huicho, L.,
D. Sanchez,
M. Contreras,
M. Paredes,
H. Murga,
L. Chinchay, and G. Guevara.
1993.
Occult blood and fecal leukocytes as screening tests in childhood infectious diarrhea: an old problem revisited.
Pediatr. Infect. Dis. J.
12:474-477[Medline].
|
| 7.
|
Manabe, Y. C.,
J. M. Vinetz,
R. D. Moore,
C. Merz,
P. Charache, and J. G. Bartlett.
1995.
Clostridium difficile colitis: an efficient clinical approach to diagnosis.
Ann. Intern. Med.
123:835-840[Abstract/Free Full Text].
|
| 8.
|
Miller, J. R.,
L. J. Barrett,
K. Kotloff, and R. L. Guerrant.
1994.
A rapid test for infectious and inflammatory enteritis.
Arch. Intern. Med.
154:2660-2664.
|
| 9.
|
Murray, P. R.,
E. J. Baron,
M. A. Pfaller,
F. C. Tenover, and R. H. Yolken (ed.).
1999.
Manual of clinical Microbiology, 7th ed.
ASM Press, Washington, D.C.
|
| 10.
|
Ruiz-Pelaez, J. G., and S. Mattar.
1999.
Accuracy of fecal lactoferrin and other stool tests for diagnosis of invasive diarrhea at a Colombian pediatric hospital.
Pediatr. Infect. Dis. J.
18:342-346[CrossRef][Medline].
|
| 11.
|
Scerpella, E. G.,
P. C. Okhuysen,
J. J. Mathewson,
R. L. Guerrant,
E. Latimer,
D. Lyerly, and C. D. Ericsson.
1994.
Evaluation of a new latex agglutination test for fecal lactoferrin in traveler's diarrhea.
J. Travel Med.
1:68-71[CrossRef][Medline].
|
| 12.
|
Silleti, R. P.,
G. Lee, and E. Ailey.
1996.
Role of stool screening tests in diagnosis of inflammatory bacterial enteritis and in the selection of specimens likely to yield invasive enteric pathogens.
J. Clin. Microbiol.
14:1161-1165.
|
| 13.
|
Speelman, P.,
R. McGlaughlin,
I. Kabir, and T. Butler.
1987.
Differential clinical features and stool findings in shigellosis and amoebic dysentery.
Trans. R. Soc. Trop. Med. Hyg.
81:549-551[CrossRef][Medline].
|
| 14.
|
Valenstein, P.,
M. Pfaller, and M. Yungbluth.
1996.
The use and abuse of routine stool microbiology. A College of American Pathologists Q probes study of 601 institutions.
Arch. Pathol. Lab. Med.
120:206-211[Medline].
|
| 15.
|
Willmore, J. G., and C. H. Shearman.
1918.
On the differential diagnosis of the dystenteries: the value of the cell exudate in the stools of acute amoebic and bacillary dysentery.
Lancet
ii:200-206.
|
| 16.
|
Wong, C. S.,
S. Jelacic,
R. L. Habeeb, et al.
2000.
The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.
N. Engl. J. Med.
342:1930-1936[Abstract/Free Full Text].
|
| 17.
|
Yong, W. H.,
A. R. Mattia, and M. J. Ferraro.
1994.
Comparison of fecal lactoferrin latex agglutination assay and methylene blue microscopy for detection of fecal leukocytes in Clostridium difficile-associated disease.
J. Clin. Microbiol.
32:1360-1361[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, January 2001, p. 266-269, Vol. 39, No. 1
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.1.266-269.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Granville, L. A., Cernoch, P., Land, G. A., Davis, J. R.
(2004). Performance Assessment of the Fecal Leukocyte Test for Inpatients. J. Clin. Microbiol.
42: 1254-1256
[Abstract]
[Full Text]
-
(2001). Fecal Leukocyte Analysis Helpful in Some Settings, But Not All. JWatch Infect. Diseases
2001: 8-8
[Full Text]